AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04866888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closure of the uterine wall defect
Description: Uterine exteriorization followed by pealing of amniotic membranes to reach an accessible pole of the placenta to detect a plan of cleavage behind it. The independent hand of the surgeon passed through the previous plan from points of least resistance to high resistance. The defect will be repaired from the inner aspect of the uterus via running sutures using Vicryl (1-0) on a round needle, 45mm. the suture will pass from one edge to hitch the bed and pass to the other edge till we completely close the defect subsequently, controlling the bleeding. Uterine scar closure by running sutures in two layers, where the first layer compresses the placental bed defect externally.
Study NCT04866888 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Before the procedure transabdominal and transvaginal ultrasound will be done to diagnose PAS and to map the uterine wall defects.~After 3 months,Transabdominal and transvaginal ultrasound with different modalities to assess the uterine wall, the cavity, endometrium, myometrium and the cervix. Isthmocele will be defined as a defect at uterine wall where residual myometrium thickness and ratio between residual myometrium and total myometrium thickness will be measured and recorded. The shape of the isthmocele will be also recorded.
Study NCT04866888 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: outpatient hysteroscopy
Description: Office hysteroscope will be done after patient consent to evaluate the uterine cavity if the patient is symptomatic or with abnormal sonography. It will be performed in the proliferative phase of the menstrual cycle. Non-steroidal anti-inflammatory will be given one hour before the procedure, then the patient will be in lithotomy position. Following aseptic rules, the rigid 4 mm hysteroscope will be inserted into the uterus through the cervix without using speculum nor tenaculum. Any pathology will be identified, and data will be recorded.
Study NCT05511493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional Erbium-YAG laser
Description: Platelet-rich plasma with fractional Erbium-YAG laser in localized stable vitiligo
Study NCT05511493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microneedling
Description: Platelet-rich plasma with microneedling in localized stable vitiligo
Study NCT04711148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04711148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orelabrutinib
Description: Orelabrutinib is a white, round, uncoated tablet
Study NCT04711148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: orelabrutinib
Description: Orelabrutinib is a white, round, uncoated tablet
Study NCT05597865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Economic Empowerment Intervention
Description: Economic Empowerment Intervention comprising Financial Literacy Sessions and Youth Development Accounts
Study NCT05597865 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alcohol and Drug Use Risk Reduction Sessions
Description: All participants in the control and treatment arm will receive Alcohol and Drug Use Risk Reduction sessions tailored for Adolescents and Youths Living with HIV.
Study NCT05597865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol and Drug Use Risk Reduction Sessions
Description: All participants in the control and treatment arm will receive Alcohol and Drug Use Risk Reduction sessions tailored for Adolescents and Youths Living with HIV.
Study NCT05010850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colovac
Description: A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
Study NCT05010850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stoma Creation
Description: Protective ileostomy
Study NCT05071495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone application
Description: Smartphone application named Signal, which connects patients and health providers
Study NCT06470789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shoulder blood restriction training
Description: Massage massage is also often used to improve the treatment of local body pain, and a large number of studies have shown that massage massage can reduce shoulder pain in the short term, restore shoulder function and improve the range of motion of shoulder joints.
Study NCT06470789 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Shoulder blood restriction training
Description: Massage massage is also often used to improve the treatment of local body pain, and a large number of studies have shown that massage massage can reduce shoulder pain in the short term, restore shoulder function and improve the range of motion of shoulder joints.
Study NCT05189613 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab
Description: Subcutaneous Mepolizumab (100 mcg) injection in patients with severe eosinophilic asthma
Study NCT05189613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Subcutaneous Mepolizumab (100 mcg) injection in patients with severe eosinophilic asthma
Study NCT05812040 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)
Description: all participants will receive Magnetic Resonance Ductography (MRD) and High-Resolution Magnetic Resonance Ductography (HR-MRD) examination, using breast dedicated coil and microscopic coil, respectively
Study NCT04713202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl
Description: Telotristat Ethyl, 250mg
Study NCT04713202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peptide Receptor Radionuclide Therapy
Description: Peptide Receptor Radionuclide Therapy
Study NCT04713202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peptide Receptor Radionuclide Therapy
Description: Peptide Receptor Radionuclide Therapy
Study NCT04713202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05834309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The intervention protocol consists of a 10-minute warm-up doing joint mobility exercises and adaptation exercises to the core exercises of the training session. The exercises will be performed at low intensity in the warm-up. During the main part of the training session, exercises will be performed on a stationary bike at a higher intensity than in the warm-up and strengthening exercises using weights and body weight exercises such as jumping jacks and squats will also be performed. All movements will be performed at 100% of the maximum speed reached in the propulsive phase (understood as executing the movement as fast as possible according to your muscular and functional capacity). The rests between sets will be between 1 and 2 minutes. At the end of the session, there will be a 5-minute return to calm by stretching.
Study NCT06188169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Increasing the inspiratory pressure if atelectasis detected by US
Description: The study used US to detect presence of lung atelectasis under mechanical ventilation in pediatrics. Inspiratory pressure increased gradually with continuous monitoring by lung US to minimize the atelectasis as possible.
Study NCT06188169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Increasing the inspiratory pressure if atelectasis detected by US
Description: The study used US to detect presence of lung atelectasis under mechanical ventilation in pediatrics. Inspiratory pressure increased gradually with continuous monitoring by lung US to minimize the atelectasis as possible.
Study NCT05573659 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: time of cutaneous recoloration
Description: In the shortest time possible (less than 3 minutes), realization of three successive measurements of the time of cutaneous recoloration by a pressure by the so-called visual method by two intensivists trained at the CRT of the surgical resuscitation service familiar with the technique of time of cutaneous recoloration. The measurements will be carried out blindly from each other.
Study NCT05573659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video assisted cutaneous recoloration
Description: Compression of the nail bed of the index of the subject studied until whitening of the pressed area, then release, the force will be equivalent to 300 g on a kitchen scale TPA 808S Techwood™ and time of compressions being of 5 seconds. Smartphone camera recording of the procedure (Iphone 7™, Apple Inc., Cupertino, CA). An assistant is in charge of timing the TRC between two tops given by the operator, the tops corresponding to the release of the pressure on the index so the beginning of the TRC and the total recoloration of the bleached area. This wizard records the three results in seconds with the associated tenth of a second.
Study NCT05093322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib in combination with Gemcitabine
Description: Surufatinib in combination with Gemcitabine
Study NCT05960071 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: protective lung strategy with recruitment manoeuvre (RM) - steady PEEP
Description: protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and steady PEEP (10) cm H2o in between RM till end of surgery.
Study NCT05960071 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: protective lung strategy with recruitment manoeuvre (RM) - decreasing PEEP
Description: protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and decreasing PEEP (15, 10, and 5) cm H20 (10 minutes for each level) in between RM till end of surgery.
Study NCT06467617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab
Description: Adebrelimab (1200 mg,IV, D1, Q3W) +~albumin-bound paclitaxel (260 mg/m2, IV, divided by D1,8,Q3W) +~carboplatin (AUC 5mg/mL/min, IV, D1,Q3W) +~recaticimab (150 mg, SC, D1,Q3W)~21-day cycle
Study NCT05613166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be administrated orally based on seizure events, with an administration interval longer than 24 hours. Participates with a body surface area (BSA) of \<= 1.2 m\^2, the dosage was 2.5 mg/time; for BSA 1.3-2.1 m\^2, the dosage was 5 mg/time; and for BSA >=2.2 m\^2, the dosage was 7.5 mg/time.
Study NCT05613166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vitamin C
Study NCT05613166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin C
Study NCT05560581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital self-efficacy training
Description: Prior to the app participation, participants will receive psychoeducation on self-efficacy and will be instructed to define two autobiographical self-efficacy memories (own achievements, e.g., completion of an exam, success in a sporting event). During the week of app participation, they will be prompted three times per day and asked to perform an imagination task. Step by step, they will recall one of their autobiographic self-efficacy memories and focus on their character traits and abilities that were relevant for their achievement.
Study NCT05560581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ecological Momentary Assessment
Description: Participants will receive questions on mood and social/virtual contacts 3 times per day.
Study NCT05560581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment
Description: Participants will receive questions on mood and social/virtual contacts 3 times per day.
Study NCT05472961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Target and Stimulus
Description: The investigators manipulate the difficulty of search for the target object by manipulating the number of distractor objects and/or the similarity between the target and distractors. The investigators manipulate the difficulty of the decision about a feature by manipulating the similarity of the feature to a criterion. The investigators manipulate the timing of when the decision feature appears on the object relative to the onset of the array and/or the onset of the saccade away from fixation in a gaze-contingent manner.
Study NCT05259579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-reflux mucosal ablation
Description: Mucosal ablation is planned around the cardia on the gastric side in a butterfly shape. Submucosal layer is raised by injecting saline with indigo carmine dye. Mucosal ablation is performed using the triangle-tip knife in spray coagulation mode.
Study NCT05378854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LifeChamps Platform
Description: Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home senor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
Study NCT05218681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Unit-based Person First Anti-stigma Awareness Rounds
Description: Educational rounds on stigma
Study NCT05218681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Individual Text-based Messaging
Description: Weekly evidence based messages to reduce SUD stigma
Study NCT05149703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mezieres Postural Treatment
Description: Implementation of 12 weeks suitable postures of Mezieres method
Study NCT05149703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mezieres Postural Treatment
Description: Implementation of 12 weeks suitable postures of Mezieres method
Study NCT05957354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active continuous Theta Burst Stimulation
Description: Each patient will receive a combination of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
Study NCT05957354 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham continuous Theta Burst Stimulation
Description: Each patient will receive a combination of stimulation sequences, including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
Study NCT04999540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: 30 mg, administered orally twice per week (BIW)
Study NCT04999540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
Study NCT05521308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Standard Curve
Description: Our current hearing aids which will be programmed to our standard frequency response curve.
Study NCT05521308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Variation #1
Description: Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
Study NCT05521308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Variation #2
Description: Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
Study NCT05521308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Variation #3
Description: Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
Study NCT05521308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Variation #4
Description: Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
Study NCT05419401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib film-coated tablet, 200 mg
Description: 400mg dose, oral, fasted
Study NCT05419401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD5363 (Capivasertib)
Description: Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous~Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted
Study NCT06442800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liver Cancer
Description: Participants will view messages about the risk of liver cancer from alcohol consumption.
Study NCT06442800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Throat and Mouth Cancer
Description: Participants will view messages about the risk of throat and mouth cancer from alcohol consumption.
Study NCT06442800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorectal Cancer
Description: Participants will view messages about the risk of colorectal cancer from alcohol consumption.
Study NCT06442800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Cancers
Description: Participants will view messages about the risk of multiple cancers from alcohol consumption.
Study NCT06442800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liver Disease
Description: Participants will view messages about the risk of liver disease from alcohol consumption.
Study NCT06442800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypertension
Description: Participants will view messages about the risk of hypertension from alcohol consumption.
Study NCT06442800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia
Description: Participants will view messages about the risk of dementia from alcohol consumption.
Study NCT06442800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking Guidelines
Description: Participants will view messages about guidelines for alcohol consumption.
Study NCT06442800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Current Warning
Description: Participants will view the current warning that is required on most alcoholic beverage containers sold in the US.
Study NCT06442800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will view neutral messages unrelated to the harms of alcohol consumption.
Study NCT04796922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.
Study NCT04796922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab will be administered intravenously on select days as per protocol.
Study NCT04796922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rituximab
Description: rituximab will be administered intravenously on select days as per protocol.
Study NCT04796922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: obinutuzumab will be administered intravenously on select days as per protocol.
Study NCT04796922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: obinutuzumab
Description: obinutuzumab will be administered intravenously on select days as per protocol.
Study NCT05338619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib 240mg (3 Tabs as Laclaza Tab 80mg) once daily in oral can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Study NCT05082584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Vadadustat tablet orally once a day for 52 weeks
Study NCT04765475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: A culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years).
Study NCT04765475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Symptom Monitoring System
Description: A daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts.